Explore the words cloud of the VEGFDANI project. It provides you a very rough idea of what is the project "VEGFDANI" about.
The following table provides information about the project.
Coordinator |
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Organization address contact info |
Coordinator Country | Germany [DE] |
Total cost | 147˙968 € |
EC max contribution | 147˙968 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2014-PoC |
Funding Scheme | ERC-POC |
Starting year | 2015 |
Duration (year-month-day) | from 2015-03-01 to 2016-08-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG | DE (HEIDELBERG) | coordinator | 147˙968.00 |
Several forms of neuroadaptation are controlled by transient increases in the nuclear calcium concentration. Nuclear calcium regulates expression of crucial genes and alterations of this signaling network likely underlie many neurological disorders. Our work led us to design two innovative strategies exploiting the therapeutic potential of nuclear calcium signaling: 1-developing direct nuclear calcium signaling activators/inhibitors (NCSA/I) and 2-manipulating expression and/or function of nuclear calcium targets. The proposed activities and budget - taking the ERC-PoC stroke study as the model project – will be used to meet the essential pre-commercial requirements prior starting up a company focusing on early drug discovery in the area of targeted nuclear calcium signaling modulation:
R&D objectives: 1-PoC to validate our lead mimicking a stroke-protective regulator: VEGFD; 2-Add novel drug targets & assays and transfer to screening partner; 3-Mass screening and lead validation to expand IP; Business objectives: 1-Manage emerging IP platform; 2-Complete fund raising during ERC funding period; 3-Close early drug discovery partnership.
As part of the ERC project 233024, we identified a nuclear-calcium dependent gene, VEGFD, as a new anti-stroke drug target. We showed that VEGFD regulates neuronal morphology and cognition and demonstrated that VEGFD delivery in the mouse brain prevents stroke-induced dendritic loss and promotes long-term recovery. We selected a highly biologically active VEGFD peptide mimetic (VPM) as our first lead for a conceptually novel nasal spray stroke therapy.
Senior business experts advised and helped us to establish a business plan and to pre-negotiate collaborative partnerships with companies and institutions required to deliver on our objectives. Thus, by partnering with industry professionals we were able to define a clear go-to-commercialization strategy while minimizing risks originating from possible lack of business experience.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VEGFDANI" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VEGFDANI" are provided by the European Opendata Portal: CORDIS opendata.
High-throughput single-cell phenotypic analysis of functional antibody repertoires
Read MoreWhy is the world green: testing top-down control of plant-herbivore food webs by experiments with birds, bats and ants
Read MorePre-natal exposure to urban AIR pollution and pre- and post-Natal Brain development
Read More